An Unstable Th Epitope of *P. falciparum* Fosters Central Memory T Cells and Anti-CS Antibody Responses

Carlos A. Parra-López¹,²*, David Bernal-Estévez¹,²,⁴, Luis Eduardo Vargas¹, Carolina Pulido-Calixto¹, Luz Mary Salazar³, J. Mauricio Calvo-Calle⁵, Lawrence J. Stern⁵*

¹ Department of Microbiology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia, ² Graduate School in Biomedical Sciences, Universidad Nacional de Colombia, Bogotá, Colombia, ³ Faculty of Sciences, Universidad Nacional de Colombia, Bogotá, Colombia, ⁴ Fundación Salud de los Andes, Research Group of Immunology and Clinical Oncology - GIIOC, Bogotá, Colombia, ⁵ University of Massachusetts Medical School, Department of Pathology and Biochemistry and the Department of Molecular Pharmacology, Worcester, Massachusetts, United States of America

Introduction

Despite a significant reduction in the incidence and number of deaths due to malaria, this disease claimed over 600,000 human lives in 2011 [1]. The widespread resistance of mosquitoes to insecticides and of malaria parasites to drugs greatly encourages the development of a malaria vaccine as a long-term solution. Vertebrates are infected when malaria-infected mosquitoes inoculate sporozoites during a blood meal. Studies in the last century demonstrated that solid and reproducible protection to malaria challenge can be achieved by immunization with sporozoites. In rodents, studies have shown that a major target of the protective immune response to sporozoites is the circumsporozoite (CS) protein [8] that uniformly cover the surface of the sporozoite. Studies in rodents and more recently in humans immunized with RTS,S a leading malaria vaccine based on the CS protein [9], or irradiated sporozoites have shown that anti-CS antibodies are higher in protected individuals than in those non-protected [7,10]. In malaria mouse model protection to sporozoite challenge was achieved by passive transfer of antibodies to the CS protein [11] and in a simian host by incubation of anti-CS antibodies with sporozoites before injection in susceptible hosts [12,13]. A major target of the anti-CS neutralizing antibodies are continuous repetitive units [13–16] located in the central region of the protein and that are characteristic of the malaria parasite species. In the human malaria parasite *Plasmodium falciparum* the repetitive units are represented by 6 copies of the minor unit (NVDP) repeats interspersed within up to 40 major (NANP) repeats. Analysis of T cell responses of individuals immunized with a synthetic vaccine [17] and of naturally exposed individuals [18] suggest that *P. falciparum* repeats are poor immunogens and antibody responses are only elicited in a restricted number of individuals of defined genotypes [19].

Responses in CD4 T cells are elicited upon engagement of T cell receptors on these cells with class II MHC (MHCII) molecules on the surface of professional antigen presenting cells (APCs).

Abstract

Malaria is transmitted by *Plasmodium*-infected anopheles mosquitoes. Widespread resistance of mosquitoes to insecticides and of malaria parasites to drugs greatly encourages the development of a malaria vaccine as a long-term solution. A major target of the antibody response to sporozoites are the repeat epitopes of the circumsporozoite (CS) protein, which span almost one half of the protein. Antibodies to these repeats can neutralize sporozoite infectivity. Generation of protective antibody responses to the CS protein (anti-CS Ab) requires help by CD4 T cells. A CD4 T cell epitope from the CS protein designated T* was previously identified by screening T cells from volunteers immunized with irradiated *P. falciparum* sporozoites. The T* sequence spans twenty amino acids that contains multiple T cell epitopes restricted by various HLA alleles. Subunit malaria vaccines including T* are highly immunogenic in rodents, non-human primates and humans. In this study we characterized a highly conserved HLA-DR6*04:01 (DR4) restricted T cell epitope (QNT-5) located at the C-terminus of T*. We found that a peptide containing QNT-5 was able to elicit long-term anti-CS Ab responses and prime CD4 T cells in HLA-DR4 transgenic mice despite forming relatively unstable MHC-peptide complexes highly susceptible to HLA-DM editing. We attempted to improve the immunogenicity of QNT-5 by replacing the P1 anchor position with an optimal tyrosine residue. The modified peptide QNT-Y formed stable MHC-peptide complexes highly resistant to HLA-DM editing. Contrary to expectations, a linear peptide containing QNT-Y elicited almost 10-fold lower long-term antibody and IFN-γ responses compared to the linear peptide containing the wild type QNT-5 sequence. Some possibilities regarding why QNT-5 is more effective than QNT-Y in inducing long-term T cell and anti-CS Ab when used as vaccine are discussed.

Citation: Parra-López CA, Bernal-Estévez D, Vargas LE, Pulido-Calixto C, Salazar LM, et al. (2014) An Unstable Th Epitope of *P. falciparum* Fosters Central Memory T Cells and Anti-CS Antibody Responses. PLoS ONE 9(7): e100639. doi:10.1371/journal.pone.0100639

Editor: Denise L Doolan, Queensland Institute of Medical Research, Australia

Received October 2, 2013; Accepted May 29, 2014; Published July 1, 2014

Copyright: © 2014 Parra-López et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by COLCIENCIAS grant No. RC-302-2010 (CD 110151928955); by DIB grant (8009074) from Universidad Nacional de Colombia – Bogotá and by NIH-AI38996 (LJS) and NIH-U19-57319 (LJS and JMCC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: caparral@unal.edu.co (CAP-L); Lawrence.Stern@umassmed.edu (LJS)
Peptides bind to MHCII molecules by a conserved network of hydrogen bonds between the peptide backbone and conserved MHCII side chains and by interactions between pockets in the MHCII binding groove and peptide side chains [20]. During assembly of MHCII-peptide complexes the peptide editor HLA-DM surveys the binding of epitopes by releasing weakly-associated peptides. This editing represents one important step in immunodominance determination. Studies on the immunogenicity of CD4 T cells for foreign viral antigens [21], model antigens [22], and antigens involved in auto-immunity [23], suggest an important role of HLA-DM in the selection of MHCII-peptide complexes with high kinetic stability. Sant and colleagues reviewed the relationship between immunodominance, HLA-DM editing, and kinetic stability of MHCII-peptide complexes and suggested that for CD4 T cell responses immunodominance is primarily due to an intrinsic property of MHC-peptide complex stability [24]. Most studies have assessed the relationship between MHCII-peptide complex stability and CD4 immunogenicity using T cell read outs such as proliferation or IL-2 and IFN-γ production [21,22,24,25]. At present there is little information regarding the impact that MHC-peptide complex stability has on the capacity of CD4 T cell epitopes to provide help for production of antibodies by B cells. In addition to antibodies, protection against P. falciparum sporozoites has been correlated with the presence of CD4 T helper cells producing IFN-γ in vaccinated volunteers [26] and naturally infected individuals living in Africa [27]. A good CD4 T helper epitope must be "universal" (recognized by CD4 T lymphocytes in MHC haplotypes widely distributed in the population). The search of universal epitopes in the CS protein has been successful; Sinigaglia identified a conserved region (CS.T3) recognized by different MHCII molecules in both mouse and man [28]; Doolan identified three promiscuous T cell epitopes (CSP-2, CSP-33 and CSP-375) recognized by HLA-DR molecules representative of the most common MHCII DR molecules worldwide [29] and Moreno and colleagues described an epitope named T* (CS 326–345) presented by multiple MHCII DR molecules [30].

The fine mapping of human CD4 T cell responses within universal epitopes and other regions of P. falciparum CS protein has identified five CD4 T helper cell epitopes designated as T1, Th2R, Th3R, CS.T3 and T* [18,30–33]. The immunogenicity of Th2R, Th3R, CS.T3 and T* has been demonstrated in clinical trials by Reece and colleagues who demonstrated that response to CS.T3 is strongly associated with protection of individuals living in Africa and by Wang [34] and Schwenk [35] that evidenced prevalent responses of CD4 T cells against Th2R, T* and CS.T3 in individuals immunized with the RTS,S malaria vaccine.

Analysis of the CD4 T cell response to the T* sequence has demonstrated that T* contains multiple overlapping epitopes that induce CD4 T cell responses in humans and mice of diverse MHC haplotypes [30,36,37]. CD4 T cell clones specific for regions contained in T* have been generated from volunteers immunized with irradiated sporozoites [30]. In a clinical trial, Nardin and colleagues demonstrated antigen specificity and function of T*-specific CD4 T cell clones isolated from volunteers immunized with a fully synthetic vaccine (T1BT*) containing the epitope T1B sequence followed by the T* epitope (DPNANPVDNAPDNV(P)3EYLNKIQNSLSTEWSPCSVT) and the peptide construct T1BT*T-Y that contains the TIB sequence followed by the T* analogue L335Y explained herein peptide QNT-5 (DPNANPVDNAPDNV(P)3EYLNKIQNSLSTEWSPCSVT) and three QNT-5 analogues at position L335: QNT-5L335YF (L335Y), QNT-5L335FY (L335F) and QNT-5L335W (L335W); fourteen alanine analogues of the QNT-5 sequence (QN-334–343); four QNT-5 truncated peptides (QN-334–343; QN-332–343; QN-335–343; QN-336–343); T1B a linear peptide containing the epitope T1 (DPNANPVDNAPDNV(P)3EYLNKIQNSLSTEWSPCSVT)

Epitope Immunogenicity and MHC-Peptide Stability

Human samples

Blood samples (400 mL) were taken and processed from healthy volunteers at the blood bank Hemocentro Distrital, Bogotá-Colombia (http://www.bogota.gov.co/tag/hemocentro-distrital), after the informed consent form was signed. This study was approved by Ethics committee of Universidad Nacional de Colombia Medical School – (protocol No. CE-159, 14 August 2009 Act. 12). Buffy-coats from DR4 volunteers handed to us by the blood bank were used to isolate PBMCs by density-gradient centrifugation over Histopaque (GE Healthcare). PBMCs were cryopreserved in 50% RPMI-1640 +40% FBS +10% DMSO in liquid nitrogen.

Peptides

Synthetic peptides included in this study HA306-318 (PKYVKQNTLKLAT), T*326–345 (EYLNIKIQNSLSTEWSPCSVT (NF-5) variant), T*326–345 (EYLNIKIQNSLSTEWSPCSVT), T*326–345 (EYLNIKIQNSLSTEWSPCSVT), three QNT-5 analogues at position L335: QNT-5L335YF (L335Y), QNT-5L335FY (L335F) and QNT-5L335W (L335W); fourteen alanine analogues of the QNT-5 sequence (QN-334–343); four QNT-5 truncated peptides (QN-334–343; QN-332–343; QN-335–343; QN-336–343); T1B a linear peptide containing the epitope T1 (DPNANPVDNAPDNV(P)3EYLNKIQNSLSTEWSPCSVT) and the peptide construct T1BT*T-Y that contains the TIB sequence followed by the T* epitope (DPNANPVDNAPDNV(P)3EYLNKIQNSLSTEWSPCSVT) and the peptide construct T1BT*T-Y that contains the TIB sequence followed by the T* analogue L335Y explained herein peptide QNT-5-L335YF (DPNANPVDNAPDNV(P)3EYLNKIQNSLSTEWSPCSVT). QNT-5-L335YF and its analogues QNT-5-Y were synthesized by 21st Century Biochemicals (Marlboro, MA), by the multiple-solid-phase technique, using tert-butyloxycarbonyl (Boc) strategy as previously described [40]. QNT-5 alanine analogues and truncated peptides were synthesized acetylated/amide at the N- and C- terminus respectively. All peptides were purified by reverse-phase High Performance Liquid Chromatography (HPLC) on a C18 Chromsphere column (Merck, Germany). The quality of the products was assayed by analytical HPLC and mass spectrometry (MALDI-TOF). The biotin-labeled peptides HA306–318 (T*326–345; T*326–345; T*326–345; T*326–345) and its analogue QNT-5-Y, were N-terminally labeled using biotin derivative sulfo-NHS-LC-Biotin (Pierce Chemical, Rockford, Illinois). The peptide (NANP)3 was kindly provided by Dr. A. Moreno (Emory University).
**Soluble Recombinant DR4**

Expression of soluble DR4 was performed using stable transfectants of Drosophila S2 Schneider cells, as described previously for DR1 [41]. Stable transfected cell lines were established by selection under 1.0 mg/L genetin (Invitrogen Life technologies – California, USA) and grown in SF900 medium (Invitrogen Life technologies – California, USA) supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin (Invitrogen Life technologies – California, USA), 250 μg/L amphotericin B and 2 mM L-glutamine (Invitrogen Life technologies – California, USA), at 22–24°C. Cell cultures were induced at a density of 5–10×10^6 per mL by the addition of 0.5 mM CuSO_4 and culture supernatant was collected 4–6 days later by centrifugation at 4000xg. Supernatant was concentrated 10-fold in a 10,000 molecular weight cut-off spiral filtration device (Millipore, Bedford, Massachusetts, USA). DR4 was purified by immunoaffinity with LB3.1-conjugated protein A column, as described [42]. The final yield of DR4 was in the range of 0.2–0.5 mg/L of cultured cells.

**Recombinant HLA-DM-molecule and DR4/peptide tetramers**

Recombinant HLA-DM was produced by expression in stably transfected S2-cells [43] essentially as described above for HLA-DR4 except that M2 (anti-flag tag) rather than LB3.1 was used for immunoaffinity. Biotinilated DR4/T*-1; DR/QNT-5; DR4/ QNT-Y peptide complexes were produced as described by Parra-Lopez et al [39].

**DR-ELISA, direct peptide-binding assays and calculation of apparent Kd values**

HLA DR4 peptide-binding studies were conducted using a modification of an ELISA-based assay [37] that consists of 3 steps: HLA-peptide complex formation, capture complex and complex detection. In this assay, HLA-peptide complex formation was achieved in 150 μL reactions containing different concentrations (0 to 4 μM) of the biotin-labeled peptides: HA306–318; T*-1327–338; QNT-5332–345; QNT-Y (L335Y) (in DMSO 10% final) and 0.05 μM purified recombinant DR4 molecules in binding buffer (100 mM citrate/phosphate buffer (pH 5.4), 0.15 mM NaCl, 4 mM EDTA, 4% NP-40, 4 mM PMSF and 40 μg/mL) for each of the following protease inhibitors: soybean trypsin inhibitor, antipain, leupeptin and chymostatin, were incubated at 37°C. After 72 hours 50 μL samples of the reactions were transferred (in duplicates) to BSA-blocked (Nunc-ELISA-Immuno-Modules Nunc-Maxisorp Loose Brand product, Denmark) previously coated with 10 μg/mL of anti-HLA-DR mAb-LB3.1 in PBS. After 2 hours of incubation at room temperature, plates were washed with PBS, 0.05% Tween-20 and incubated for 1 hour with alkaline phosphatase-labeled streptavidin (Vector Laboratories, Burlingame, California, USA). Captured biotin-labeled peptide/DR4 complexes were revealed with 4-nitrophenylphosphate substrate (Kirkegaard and Perry Laboratories, Gaithersburg, Maryland, USA). For determining peptide binding competition assays unlabeled peptides at concentrations ranging from 0 to 100 μM were mixed in binding buffer together with biotin-labeled HA peptide (0.025 μM) and DR4 molecules (0.05 μM) in a final 150 μL volume and the reactions incubated for 72 hours at 37°C. Competition assays were revealed using DR-ELISA described above, IC_{50} was calculated by minimal squares and percentages of DR4 binding inhibition were calculated by using the formula: 100×(1-[OD_{105 nm in the presence of competitor}/OD_{405 nm in the absence of competitor peptide)].

**Assay of dissociation kinetics**

Association reactions of DR4 with each of the biotin-labeled peptides T*-1; QNT-5; QNT-Y and HA were performed by incubation of 1 μM DR4 molecules with 10 μM biotin labeled peptide in 400 μL binding buffer for 72 hours at 37°C. Biotin-labeled peptides were removed from reactions by gel filtration using Sephadex G50 columns. The reaction was then diluted 1:2 with binding buffer and split in two tubes (400 μL each). The dissociation reactions in presence and absence of HLA-DM were started by adding to one tube dissociation mix having 10 μM unlabeled HA peptide and 1 μM HLA-DM and to the second tube only 10 μM unlabeled HA peptide in a final volume of 2 mL. At different time points, 200 μL aliquots of each dissociation reaction (+/- HLA-DM) were transferred into tubes having 20 μL of 1 M Tris pH 8.0 that were frozen immediately in ethanol/dry ice and stored at −70°C until use. The thawed dissociation mixtures were incubated in anti-DR1 Ab LB3.1 precoated 96-well Lumitrac 600 white plates (USA Scientific, Ocala, FL, USA) at 4°C for 3 h, washed three times with PBS + 0.05% Tween-20, incubated with Europium-streptavidin at 37°C for 1 hour, washed again, and then mixed with Europium enhancement solution to release EU3+ (PerkinElmer, Shelton, CT, USA). A Victor plate reader (PerkinElmer, Shelton, CT, USA) was used to read the time-resolved fluorescence of EU3+. The dissociation curve was fitted to single-phase exponential decay with constraint 100% bound at time 0 in GraphPad Prism 5 (GraphPad software, San Diego, CA, USA) to determine the off rate, k_{off}, and half-life.

**Epitope Immunogenicity and MHC-Peptide Stability**

**Molecular modeling**

The X-ray crystal structures of a complex of a human alpha/beta-TCR influenza HA antigen peptide and DR4 (PDB code 1J8H) [44] and DR4 with a peptide mimetic inhibitor of antigen presentation by HLA-DR class II MHC molecules (PDB code 1DSZ) [45] were used as template for further modeling. The total energy interaction of HA or peptide mimetic inhibitor with DR4 were determined first without including any further refinements using docking software (Accelrys Software Inc., San Diego, California, USA) run on an Indigo 2 Station (Silicon Graphics, Sunnyvale, California, USA). In order to obtain the energetic interaction of minimized peptide structures interacting with DR4, the Discovery 3 program (Accelrys, San Diego, California, USA) was used for simple minimization strategy using 20000 steps and 0.0001 A RMSD. For modeling peptides QNT-Y and QNT-5 interacting with DR4, amino acids side chains of template peptides were replaced by QNT-3 (LSTETWSPCS) and QNT-Y (YS-TETWSPCS) side chains and the free energy of interaction of side chains of amino acid residues of both peptides with corresponding DR4 pockets (reported as explicit van der Waals (VDW) energy...
values) were determined with and without further refinements. To analyze putative anchor residues at P1 in modeled peptides QNT-5 and QNT-Y, the intermolecular energy of residues occupying P1 on template peptides HA and peptide mimetic inhibitor (Y and cyclohexylalanine (Cha) respectively) was compared to those of L and Y acting as P-1 anchoring residues of the QNT-5 peptide sequence.

**Immunization of DR4 transgenic mice**

HLA-DR4 transgenic mice from Taconic Farms housed at the University of Massachusetts in Worcester MA animal facility were used in the experiments. Animals were handled and euthanized according to University of Massachusetts Medical School Institutional Animal Care and Use Committee approved through the Animal Protocol A-1419. Three groups of four DR4 transgenic mice (HLA-DRα1*01:01/DRβ1*04:01) were immunized subcutaneously at the base of the tail with 50 μL of an emulsion containing 50 μg of peptide T1B, T1BT* or T1BT*-Y in Montanide ISA 720 as adjuvant or adjuvant alone as control. Mice were immunized with two or three doses of the peptides or adjuvant (20 days apart). One hundred to two hundred microliters of blood was obtained from the facial vein of each experimental mouse by a trained technician before each immunization.

**Antibody titer determination**

Anti- *P. falciparum* CS repeat immunoglobulin G (IgG) titters were determined in individual serum samples by enzyme-linked immunosorbent assay (ELISA) using immobilized (NANP)₆ peptide, peroxidase-labeled species-specific anti-IgG antibody, and 2,2-azonio bis(3-ethylbenzthiazolinesulfonic acid) (ABTS) substrate. Antibody titers were defined as the highest serum dilution that yielded an ABTS optical density greater than the optical density observed for the mean plus three standard deviations of pre-immune serum. IgG subtypes were determined by ELISA using biotin-labeled monoclonal antibodies to IgG1, IgG2a, IgG2b and IgG3 (Biotengend) followed by peroxidase-labeled streptavidin and ABTS. Each assay plate included positive control wells covered with mouse IgG, IgG1, IgG2a, IgG3b or IgG3 (all from BD Biosciences). A control monoclonal antibody (2A10) was used.

![Figure 1. Identification of residues in QNT-5 critical for binding to DR4.](image-url)

A series of QNT-5 analogues with single alanine substitutions (A) and N- and C-terminal truncated QNT-5 peptides (B) were synthesized and tested at concentrations ranging from 0 to 100 μM for their ability to bind to DR4. Relative binding was measured in a binding inhibition assay. The concentration of each alanine analogue or truncated peptide required to reduce the binding of a biotin-labeled test peptide to 50% (IC₅₀) is shown. The test peptide was a biotinylated version of HA (306PKYVKQNTLKLAT318), a peptide from influenza hemagglutinin that binds strongly to DR4. Under the conditions used in this set of experiments, the IC₅₀ for the HA peptide was 0.31 ± 0.05 μM (Table S1). Representative findings from 3 experiments performed are shown (each point was performed in duplicate). Bars represent SD.
also as a positive control for antibody responses to the *P. falciparum* CS repeats [46].

**Determination of IFN-γ responses by ELISPOT in splenocytes of DR4 transgenic mice immunized with T1BT* or T1BT*-Y**

IFN-γ ELISPOT was performed using IFN-γ ELISPOT Kit as manufacturer instructions (eBiosciences, San Diego, CA, USA) in PVDF plates (Millipore, Billerica, MA, USA). In brief, plates were covered with 100 μL of capture antibody and after overnight incubation at 4°C washed and blocked with RPMI-1640 +10% FCS. Subsequently, 10° splenocytes in 100 μL of RPMI supplemented with 10% FCS were seeded per well and peptides (T*-1, QNT-5, QNT-Y, HA) at a final concentration of 10 μg/mL added. After 48 hours incubation at 37°C, 5% CO2 plates were washed 3 times with 1× PBS, 0.05% Tween-20 and cytokine revealed by successive incubation with detection antibody, wash, peroxidase-HRP incubation, wash and final visualization with AEC substrate. Plates were scanned and spots counted with the help of an immunospot Analyzer (CTL-immunospot S6, Cellular Technology Limited, USA).

**Quantification of human CD4 T cells specific for T*-1; QNT-5 and QNT-Y epitopes generated from naïve CD4 T cells primed in vitro with T1BT* and T1BT*-Y**

Specific cell lines against T1BT* and T1BT*-Y peptide constructs were generated from naïve CD4 T cells from a HLA-DRb1*04:01 donor using as APCs autologous monocyte derived dendritic cells (DCs) as described by Moser and colleagues [47]. CD4 T cells were purified using a naïve CD4 T cell isolation kit as manufacturer instructions (Miltenyi Biotec, Germany). DCs were pulsed with 3.75 mM of peptides T1BT* or T1BT*-Y. DCs were matured with TNF-α (25 ng/mL). Cells were co-cultured at 37°C, 5% CO2 for 14 days and re-stimulated at 1:10 ratio with mature dendritic cells pulsed with 3.75 mM of the same peptide used to prime. Seven days after the cells were stained with fluorescent DR4/T*-1; DR4/QNT-5 and DR4/QNT-Y tetramers assembled by stepwise addition of streptavidin-PE (Caltag, Life technologies – California, USA) to biotinylated HLA-DR4–peptide complexes at a final molar ratio of 1:4 as described [41]. T cells were incubated with tetramers for 4 hours at 37°C followed by 20 min incubation with cell surface markers: anti-CD3 PE-Cy7, anti-CD4 PE-Texas red (Beckman Coulter, Palo Alto CA, USA), anti-CD45RO FITC, anti-CD62-L PECy5 (all from BD Biosciences). San Diego CA, USA) on ice before washing with ice-cold buffer. Tetramer and Ab binding were determined using an FACS Aria II flow cytometer (BD Biosciences).

**Statistical analysis**

Raw ELISPOT data was analyzed by Kruskal-Wallis test with Dunn’s Multiple Comparison Test to compare numbers of IFN-γ spot forming units (IFN-γ SFU) between splenocytes of mice immunized with peptide and control mice (vaccinated with adjuvant only) upon stimulation in vitro with various assay antigens (T1BT*, T1BT*-Y, T*-1; QNT-5, QNT-Y, T1 and HA306–318). Anti-repeat antibody titers were analyzed with Mann Whitney test.

**Results**

**Identifying anchoring residues for QNT-5 binding to DR4**

In a previous study we described two overlapping HLA-DR4-binding epitopes within the universal CD4 T cell epitope T* from...
P. falciparum [39]. MHC and T cell interactions were described for T*1, an epitope near the N-terminus of the T* peptide (CS327–338, YLNKIQNSLSTE). A second epitope termed T*-5 (334SLSTEWSPCSV344) was mapped near the C-terminus of the T* peptide, but was not fully characterized. Previous publications that analyzed antigen-specific CD4 T cell clones isolated from DR4 individuals vaccinated with a synthetic peptide vaccine (T1BT*)4-Pam3Cys found that some of these clones recognized the core SLSTEWSP sequence contained in T*-5 [36,38]. To perform a fine mapping of the C-terminal epitope, and to analyze side-by-side its HLA-DR4-binding interactions with those of T*, T*-1, and control tight-binding viral peptide HA derived from influenza hemagglutinin, we synthesized a series of peptide variants based on QNT-5 (332QNISLSTEWSPCSV345) (Table 1). The QNT-5 peptide corresponds to the T*-5 sequence elongated by two and one residues at the N- and C- terminus of the core respectively. We performed binding competition assays between biotin-labeled HA and a set of unlabeled single alanine substitution analogues and truncation variants of QNT-5. IC₅₀ values for these peptides are shown in Figure 1A and Table S1. Alanine substitution of L335 or S340 greatly decreased binding of QNT-5 (as indicated by high IC₅₀ values) with smaller effects observed upon substitution of E338 and P341. These effects are consistent with a binding frame in which L335, E338, S340 and P341 of the QNT-5 peptide (black

| Table 2. Interaction with HLA-DRβ1*04:01 of HA and DR4 epitopes of T*. |
|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Peptide | Kₐ (nM) | Kₐ (nM) | Half-life (min) | Half-life DM (min) | DM-sus (10⁻² min⁻¹ μM⁻¹) (c) |
| T*       | 248±75.1 (a) | 123.15±1.05 | ND | ND | ND |
| T*-1     | 42.61±22.84  | 51.59±9.30  | 3831 (b) | 294 | 2.14 |
| QNT-5    | 504.23±86.23 | 714.1±3.90  | 304.8 | 105 | 4.33 |
| HA       | 42.81±39.93  | 44.77±39.77 | 37200 | 5472.6 | 0.11 |
| QNT-Y    | 25.47±10.70  | 35.67±20.50 | 8307 | 2589 | 0.18 |

a) Apparent equilibrium binding affinity.

b) Dissociation half-life from single exponential decay.

CIDM susceptibility. DM-sus was calculated by (k_off,DM·k_off,in)/[DM] as described by Yin et al. [4] where k_off,DM = ln²/kd,D₄ and k_off,in = ln²/kd,DR4, and [DM] = 1 μM.

ND. Not done.

doi:10.1371/journal.pone.0100639.t002

Figure 2. Dissociation kinetics from DR4 of HA, T*-1 and QNT-5 peptides measured in presence and absence of HLA-DM. (A) Amino-acid sequence and location of T*-1 and QNT-5 epitopes in T*. (B) Characterization of the dissociation behavior of peptide MHC complexes formed after 72 h of complex formation. The curves shown represent single or double exponential decays that fit the data. Filled symbols represent the decays values of the 3 DR4-peptide complexes in the presence of HLA-DM. Empty symbols represents the decay values of the complexes in the absence of HLA-DM. A representative experiment from 2 experiments performed is shown (each time point was carried out in duplicate).

doi:10.1371/journal.pone.0100639.g002
WSPCSVT) is highly tightly to HLA-DR4 than did QNT-5, with apparent concentration of HLA-DR4 (see Methods). T*-1 bound more assays using biotinylated variants of T*-1 and QNT-5 with a fixed equilibrium.

as a peptide-exchange catalyst but does not alter the binding (Kd) values of 0.9 and 0.2 M, respectively.

Figure 3. VDW energy value for the hydrophobic interactions at P1 between DR4 and QNT-5 or an analogue of QNT-5 with a L335Y substitution at P1 (peptide QNT-Y). VDW value after the computational docking of peptides QNT-5 and QNT-Y into an MHC (DR1*04:01) structure, originally determined for the HA peptide and peptidomimetic inhibitor complexes, with a tyrosine[44] (left panel) and a cyclohexylalanine[45] side chain at P1 [45] (right panel), respectively. The height of the white- and dashed-boxes represents the VDW free energy value expressed in eV for QNT-5 (L) with the anchor residue L335 at P1 and for QNT-Y (Y) with Y318 at P1, respectively. doi:10.1371/journal.pone.0100639.g003

arrowheads in Figure 1A) bind in the canonical P1, P4, P6, and P7 pockets of HLA-DR4 [20,48,49]. As previously observed for other [20,48–50] HLA-DR4-binding peptides alanine substitution at the P9 position (S334) did not have a significant effect on QNT-5 binding (Figure 1A). Truncation analysis (Figure 1B) suggests that peptides need to extend at least to the P(-1) position, since deletion of S334 (QN335-343) significantly reduced binding to HLA-DR4, even though the S334A substitution did not have a significant effect (Figure 1A).

Apparent binding affinity (Kd) of peptide complexes in presence and absence of HLA-DM

Previously we reported that T*-5 peptide bound to HLA-DR4 more weakly than the T*-1 peptide as evaluated by a competition binding assay, with IC50 values of 0.9 and 0.2 μM, respectively [39]. To evaluate the binding affinity more precisely and to compare T*-1 and QNT-5 directly, we performed direct binding assays using biotinylated variants of T*-1 and QNT-5 with a fixed concentration of HLA-DR4 (see Methods). T*-1 bound more tightly to HLA-DR4 than did QNT-5, with apparent Kd values of tenfold lower, ~42 nM versus ~504 nM, respectively (Table 2 and Figure S1). Apparent Kd was similar in presence of HLA-DM (~51 and ~714 nM respectively), as expected since HLA-DM acts as a peptide-exchange catalyse but does not alter the binding equilibrium.

DR4/QNT-5 peptide complexes are highly unstable

We also evaluated the kinetic stability of purified DR4/T*-1 and DR4/QNT-5 complexes (Figure 2, Table 2). DR4/T*-1 formed a stable complex with half-life ~3800 min at 37°C, although dissociation was still much quicker than for the prototypical tight-binding viral peptide HA (half-life 37,000 min). DR4/QNT-5 formed a much less stable complex, with half-life ~300 min. HLA-DM increased the dissociation of both DR4/T*-1 and DR4/QNT-5 (half lives of ~300 and ~100 min respectively).

DR4/QNT-5 peptide complex instability can be reversed by a tyrosine in QNT-5 occupying P1

Published results from Sant and others suggest that immunodominance in CD4 T cell responses is primarily an intrinsic property of peptide-class II complex stability that can be modulated by manipulating MHC-peptide interactions [22]. The unstable behavior DR4/QNT-5 led us to predict that it would be poorly immunogenic and that this could be solved by the rational modification of MHC-peptide complex stability. The T*-1 sequence is highly variable, with more than 28 variants reported [51–53]; in contrast, QNT-5 (QNSLSTEWSPCSVT) is highly conserved throughout several Plasmodium species and harbors a sequence that overlaps with the region II sequence of the CS protein (underlined) that is crucial for the entrance of sporozoites into hepatocytes [36,57]. These attributes of QNT-5 and the fast off rate of DR4/QNT-5 complexes even in absence of HLA-DM (see Table 2) prompted us to focus our search on the structural features of this sequence responsible for its unstable behavior using a combination of computational and experimental approaches. First, we analyzed the QNT-5 sequence using Propred [58], which is a matrix-based algorithm that can be used for predicting peptide binding to any MHC class II alleles, including the HLA-D瑞*04:01 allele. Because this algorithm typically identifies strong allele-specific preferences at positions P1, P4, P6 and P9, based on docking data, we oriented the analysis to search for amino acid substitutions at P1 that would improve binding of QNT-5 to DR4. The results of these analyses predicted that the QNT-5 peptide sequences with aromatic residues Y, F and W substituted for L335 at P1 would enhance peptide binding (data not shown). Second, a docking program for evaluating the probability of MHC-peptide complex formation was used to determine the explicit VDW energy value of the hydrophobic interactions at each putative residue of the QNT-5 and QNT-Y (a QNT-5 analogue having L335Y substitution at P1) peptide sequences occupying the P1, P4, P6 and P9 pockets at the peptide-binding groove of DR4 (β1*04:01). After computational docking into a MHC structure originally determined for a HA peptide complex [44], significant differences between the QNT-5 and QNT-Y peptides were observed only at the P1 pocket, as expected. The free energy of this residue at P1, estimated by the VDW force value for QNT-5 with the anchor residue L335 at P1, was ~18.56 eV, which is substantially higher than that of Y318 with ~42.06 eV (Figure 3 and data not shown). The same analyses were performed using a different MHC structural model consisting of a complex with a peptidomimetic inhibitor that contains a cyclohexylalanine side chain at P1 [45]. The same pattern was observed, with free energies of ~19.91 eV after minimization for L335 at P1 and ~35.96 eV for Y318 (Figure 3 and data not shown). Thus, Y318 was predicted to be more favorable in the P1 pocket than L335, regardless of the starting model used for the calculations. This information, together with the results of the algorithm prediction of a peptide analogue of QNT-5 containing the L335Y substitution at P1 (QNSYSTEWSPCSVT), hereafter named QNT-Y (Figure 4A), which predicted a higher stability of Y over L335 at P1 in DR4, led us to hypothesize that the DR4/QNT-Y peptide complex might exhibit greater stability than the DR4/QNT-5 complex.

In order to evaluate experimentally whether a P1 substitution could stabilize QNT-5 peptide, we performed competition binding assays (IC50) for QNT-5, QNT-Y and the control tight-binding HA peptide (Figure 4B). QNT-Y binds to DR4 with a relative
affinity ~10-20-fold higher than QNT-5 (IC50 ~130 nM vs. ~1700 nM) (range values 124.2–139.9 and 1528–1848 (95% CI) respectively). The higher affinity of QNT-Y for DR4 was evaluated also in a direct binding assay using biotinylated peptides, in the presence and absence of HLA-DM. Compared to QNT-5, the binding affinity of QNT-Y was increased ~20-fold with apparent Kd values with and without HLA-DM of ~36 and ~25 nM, respectively (Table 2). Finally, having found that QNT-Y exhibited a higher affinity for DR4, we sought to examine the impact of the L335Y change at P1 on the kinetic stability of the DR4/QNT-Y complex as well as the sensitivity of this peptide complex to HLA-DM editing. We observed a ~25-fold increase in the half-life of DR4/QNT-Y compared to DR4/QNT-5 complexes in presence or absence of HLA-DM (lifetimes of ~2,500 and ~8,300 min, respectively (Figure 4C and Table 2)). These results clearly demonstrate that the L335Y substitution at P1 reverses the unstable behavior of the DR4/QNT-5 peptide.

In DR4 transgenic mice a linear peptide malaria vaccine candidate containing QNT-Y elicits higher anti-CS repeat antibody titers than a peptide containing QNT-5 but the effect is transient and long-term responses are reduced stability in CD4 T cell immunodominance hierarchy and the capacity to function as T helper epitopes in the anti-(NANP)3 antibody response. To determine the relative T helper activity of QNT-5 and QNT-Y two peptides were synthesized, T1BT* and T1BT*-Y (having the stable L335Y substitution in QNT-5 (Figure 5A)). Both peptides have in common the T1B sequence that contains the minor T1 epitope [19,31] and three copies of the NANP repeat that is the major antibody epitope in the P. falciparum CS protein. Although T1 functions as a T cell epitope in DR4 haplotype malaria-immune individuals [19,31] we do not expect significant T cell responses to T1 in DR4 transgenic mice immunized with T1BT for two reasons: (i) in previous studies, a DR4 individual immunized with a construct containing T1BT* developed T cell response to T* but not to T1 [36,38] and (ii) contrary to QNT-5 and QNT-Y (IC50 ~25 and ~500 respectively, Table 2), T1 binds very weakly to DRB1*04:01 (IC50 ~18000 nM, not shown). The “B” sequence functions as a reporter for anti-CS repeat antibody responses, although “T1” sequences are also recognized. We used this construct because previous studies demonstrated that T1BT* is highly immunogenic in humans [36,38] and also because T1BT*-immunized mice are protected when challenged with sporozoites in a murine malaria model for P. falciparum [39].

Figure 4. Binding activity of QNT-Y and stability of the DR4/QNT-Y peptide complex. (A) Amino-acid sequence of QNT-5 and QNT-Y peptide analogue. (B) Competition binding assay for QNT-5, QNT-Y and HA. The plots show the binding inhibition of the biotinylated HA306-318 peptide to DR4 using increasing amounts (0 to 20 μM) of unlabeled peptides to calculate the concentration of each peptide required to reduce the binding of a biotin-labeled test peptide to 50% (IC50). Under the experimental conditions used here, the IC50 for the HA peptide was ~172 μM. Representative results from 1 of 3 experiments performed are shown (each point was performed in duplicate). (C) Dissociation kinetics of the QNT-5 and QNT-Y peptides from DR4, measured in the presence (filled symbols) or absence (empty) of HLA-DM. A representative experiment of 3 performed is shown (each time point was performed in duplicate). Bars represent SEM.

doi:10.1371/journal.pone.0100639.g004
DR4 transgenic mice were immunized with T1BT* and T1BT*-Y following a typical vaccination protocol, with three immunization doses spaced 20 days apart collecting blood samples before each immunization (days 0, 20, 40) and at days 67 and 85 after first dose (Figure 5B). Antibody titers throughout the immunization scheme shown in figure 5B are summarized in Figure 5C and Table 3. Figure 5C shows that 20 days after the first dose, anti-(NANP)6 antibody titers in sera of mice immunized with peptide T1BT*-Y (filled circles) were significantly higher ($p < 0.001$) than those detected in mice immunized with T1BT* (open circles). However, anti-(NANP)6 antibody titers in sera of both groups of animals were similar by the second dose, and antibody titers in mice vaccinated with T1BT*-Y did not sustain in the long term. Two months after the third dose the anti-(NANP)6 antibody titers in mice vaccinated with T1BT*-Y were significantly lower ($p < 0.05$) than in mice vaccinated with T1BT* (Figure 5C). The role of T* as a T helper epitope in the antibody response to (NANP)6 elicited by immunization with T1BT* or T1BT*-Y was corroborated by a lack of antibody responses in DR4 transgenic mice immunized with T1B (Table 3). Using the same immunization scheme shown in figure 5B, only one of four DR4 transgenic mice immunized with a linear T1B peptide developed anti-(NANP)6 antibody response, and this response was very weak with titer 1:80 as compared to titers over 1:1000 in T1BT* and T1BT*-Y immunized mice (Table 3). This led us to conclude that anti-(NANP)6 antibody responses observed upon immunization of DR4 transgenic mice with T1BT* or T1BT*-Y are mostly associated with help by T*.

Isotype specificity of the anti-repeat response elicited by vaccination with T1BT* and T1BT*-Y

IgG isotype responses to T1BT* and T1BT*-Y in immunized mice are presented in Figure 6. Mice immunized with these constructs produce an early IgG1 response, with T1BT*-Y inducing a stronger response. T1BT*-Y-immunized mice also produced IgG2b and a low levels of IgG2a. Following a second dose total IgG and IgG1 responses have similar strength in both groups of mice, and IgG2b responses are now also observed in T1BT* immunized mice (Figure 6B). Finally, after a third dose the IgG2b antibody responses in T1BT*-Y are appreciably lower than in T1BT* immunized mice (Figure 6C). Overall this pattern is similar to that observed for the IgG titers reported in Figure 5C. None of the constructs induced IgG3 responses to (NANP)6 peptide.

Peptides containing QNT-5 and QNT-Y epitopes elicit IFN-γ responses in DR4 transgenic mice

T cell responses elicited by T1BT* and T1BT*-Y were assessed in splenocytes of DR4-transgenic mice using IFN-γ as a readout. IFN-γ responses were measured in vitro after stimulation with various assay antigens (T1BT*, T1BT*-Y, T*-1; QNT-5, QNT-Y, QNT-Y).

### Table 3. Anti-(NANP)6 antibody responses in DR4 transgenic mice after three subcutaneous immunizations with synthetic peptides in Montanide ISA 720.

| Immunogen | Responders/Total | GMT* | Ab Titer Range |
|-----------|------------------|------|----------------|
| T1BT*     | 4/4              | 17222| 10240–40960    |
| T1BT*-Y   | 4/4              | 1810 | 1280–2560      |
| T1B       | 1/4              | 80   | <1:80–80       |

*Geometric Mean titers (GMT) and Range of antibody titers in the group of mice immunized with peptides indicated in the first column.

doi:10.1371/journal.pone.0100639.g005

doi:10.1371/journal.pone.0100639.t003
T1 and HA 306–318) and compared to splenocytes from mock-immunized animals. The experimental protocol is shown in figure 7A, and figure 7B summarizes the results observed after 2nd dose (red symbols) and 3rd dose (gray symbols) immunization. In general the observed responses were considerably weaker than those previously reported in non-transgenic mice using a similar immunization and assay strategy [59]. The responses in T1BT* (diamonds) and T1BT*-Y (circles) immunized mice to their respective immunogens were significantly higher than those in control mice (squares, immunized with PBS/montanide). Weak responses to QNT-5 and QNT-Y peptides were also observed. IFN-γ responses to T*-1, T1 and the control HA peptide were not significantly higher than those in control mice for either immunogen. Overall no significant difference in the IFN-γ response to any assay antigen was detected in comparisons of mice immunized with T1BT* and T1BT*-Y.

IFN-γ response to QNT-Y wanes over time and at forty-five days after third dose is weaker than the response to QNT-5

Antibody responses in T1BT*-Y were lower over time when compared with T1BT* immunized mice (Figure 5C). To evaluate if the IFN-γ T cells response to QNT-5 and QNT-Y followed a similar trend, splenocytes were obtained from mice immunized with T1BT* and T1BT*Y 45 days after the third immunization dose (Figure 7A) and their IFN-γ response determined as above. We found that similarly to antibody responses, IFN-γ responses at 45 days to both QNT-5 and QNT-Y were significantly greater in mice vaccinated with T1BT* as compared to T1BT*-Y (Figure 7C). Moreover responses in T1BT*-Y mice were not significant as compared to those in control mice. These results suggest that QNT-5 is more effective than QNT-Y in inducing long-term IFN-γ T cells.

IFN-γ T cells response to QNT-Y

Human CD4 T cells primed in vitro with QNT-5 exhibit a central memory phenotype and are cross reactive with QNT-Y

Successful vaccination relies in the generation of long-term memory T cells. The higher long-term Ab and IFN-γ cellular responses induced by the T1BT* construct as compared to T1BT*Y suggests that QNT-5 fosters the generation of central memory T cells more efficiently than QNT-Y despite the improved HLA-DR4 binding of QNT-Y. To investigate this in a human setting, we looked at the ability of T1BT* and T1BT*-Y to prime naïve CD4 T cells 	extit{ex vivo}. DCs were pulsed with T1BT* or T1BT*Y and incubated together with naïve CD4 T cells, and three weeks later the cells were stained with anti-CD3, anti-CD4, anti-CD62L, anti-CD45RO antibodies and with DR4 fluorescent tetramers specific for T*-1; QNT-5 and QNT-Y (Figure 8A). The use of fluorescent tetramers allowed us to compare the percentage of CD4 T cells responding to each epitope as well as the percentage of responding cells in memory and effector compartments. DR4/QNT-5 and DR4/QNT-Y tetramer-positive cells were detected in cultures that had been primed with either T1BT* or T1BT*-Y (Figure 8B). T cells elicited against QNT-5 cross-reacted with QNT-Y and vice versa (Figure 8B). The priming of naïve CD4 T cells with T1BT* led into a more vigorous expansion of central memory CD4 T cells specific for QNT-5 than observed for QNT-Y in cells primed with T1BT*Y (14.9% vs. 4.51% of TCM respectively in figure 8D and table 4). The percentages of effector CD4 T cells specific for each epitope (TEF or TEM in table 4), were not remarkably different between cultures primed with either T1BT* or T1BT*-Y.

Discussion

In spite of significant advances in the understanding of the biology of 	extit{Plasmodium} parasites and the immune response elicited...
by these pathogens, there is not yet a subunit vaccine capable of eliciting long lasting protection. Multiple studies have demonstrated that antibodies to the repeat units in the CS protein can neutralize *Plasmodium* sporozoites [13,60–63]. In humans, although protected individuals have higher anti-repeat antibody titers than non-protected individuals, the correlation between protection and anti-CS antibody titers is not perfect (reviewed in [9,64]). A major limitation for a *P. falciparum* vaccine based on antibody responses is that the CS repeats region does not elicit T cell responses in most individuals [18,19]. The search for CD4 T cell epitopes in the *P. falciparum* CS protein has resulted in the identification of 4 T cell epitopes in the C-terminal region of this protein designated as a T*, Th2R, Th3R and CS.T3 [18,30,33]. T cell responses to Th2R, Th3R and T* have also been reported in vaccines immunized with the malaria vaccine RTS,S [35]. Genetic variability in *P. falciparum* CS regions that harbor Th2R and Th3R [18,55,65] is a major consideration in vaccines engineered with these T helper epitopes [54,66,67]. However, it is not clear if polymorphism is a consequence of immunological pressure [55,68].

In this work we studied a highly conserved C-terminal epitope from T* designated as QNT-5. Contrary to other major CD4 T cell epitopes (T*-1, Th2R and Th3R) [18,30,39], QNT-5 spans a highly conserved sequence and for this reason is a very attractive...
Epitope Immunogenicity and MHC-Peptide Stability

A

Prime

\[ \text{T1BT}^* \text{ pulsed DCs} \quad \text{Naive CD4 T-cells} \]

\[ \text{T1BT}^* \text{ pulsed DCs} \]

\[ \text{T1BT}^* \text{ pulsed DCs} \quad \text{Naive CD4 T-cells} \]

Boost

\[ \text{T1BT}^* \text{ pulsed DCs} \]

\[ \text{T1BT}^* \text{ pulsed DCs} \]

\[ \text{Tetramer staining and flow cytometry analysis} \]

B

\textit{In vitro} priming of CD4 T cells from \textit{DRB1*04:01:01} healthy donor with:

\[ \text{T1BT}^* \]

\[ \text{T1BT}^* \text{-} \text{Y} \]

C

\textit{In vitro} priming with:

\[ \text{T1BT}^* \]

\[ \text{T1BT}^* \text{-} \text{Y} \]

D
The TN, TCM, TEM or TEMRA T cell sub-populations after 21 days in culture. (C) CD4+ naive (TN) (CD45RO- CD62-L+), central memory (TCM) (CD45RO+ CD62-L+), effector (TEM) (CD45RO+ CD62-L-) and terminal effector (TEMRA) (CD45RO- CD62-L-) T cell sub-populations were identified using flow cytometry by staining the cells after 21 days in culture with fluorescently labeled anti-CD45RO and anti-CD62-L antibodies. The numbers in the plots correspond to the percentage of each sub-population among CD3+CD4+ double-positive T cells. (D) Plots showing the percentages of CD4 T cells positive for QNT-5 and QNT-Y tetramers present among the TN, TCM, TEM or TEMRA T cell sub-populations after 21 days in culture.

doi:10.1371/journal.pone.0100639.g008

Table 4. Percentage of tetramer positive CD4 T cells in different CD4 T cell sub-populations.

| Cell line | Tetramer | % TN | % TCM | % TEF | % TEM |
|-----------|----------|------|-------|-------|-------|
| T1B7*     | T*-1     | 0.76%| 7.68% | 0.87% | 1.99% |
|           | QNT-5    | 0.00%| 14.9% | 1.1%  | 1.57% |
|           | QNT-Y    | 0.25%| 7.3%  | 0.34% | 0.84% |
|           | SA-PE    | 0.00%| 0.06% | 0.00% | 0.00% |
| T1B7*-Y   | T*-1     | 0.00%| 8.19% | 0.79% | 1.17% |
|           | QNT-5    | 0.18%| 4.51% | 1.94% | 1.0%  |
|           | QNT-Y    | 0.43%| 4.34% | 0.45% | 0.78% |
|           | SA-PE    | 0.00%| 0.06% | 0.00% | 0.00% |

doi:10.1371/journal.pone.0100639.t004

Epitope Immunogenicity and MHC-Peptide Stability

epitope for subunit vaccine development. We identified a DR4-binding register in QNT-5 characterized primarily by pocket 1 (L(335)) and pocket 6 (S(340)) anchor residues with smaller contributions from pocket 4 (E(338)) and pocket 7 (P(341)). Measurement of different biophysical parameters of this MHCII-peptide interaction revealed the highly unstable character of DR4/QNT-5 complex in the presence of HLA-DM. As a step toward the development of a strategy for stabilizing this MHC-peptide interaction in the presence of HLA-DM, we investigated the role of the pocket 1 (P1) side chain, thought to be the major determinant of HLA-DR binding. An MHCII-peptide complex stable in the presence of HLA-DM was achieved after improving the binding capacity of QNT-5 to HLA-DR4 by replacing the naturally occupying L(335) residue at P1 with the optimal P1 side chain tyrosine. Previous studies of some peptide-based vaccines have enhanced immunogenicity by improving MHC-peptide interactions [69–71]. The in vitro peptide binding results reported here suggested that this approach might potentially provide a possible strategy to improve the immunogenicity of malaria vaccine candidates based on T*. However, in vivo studies in DR4 transgenic animals indicated that any improvement in immunogenicity due to stabilizing the MHC-peptide interaction was modest and transient, and the unstable parent QNT-5 epitope elicited better long-term immune responses than the stable modified QNT-Y.

Our in vitro peptide binding studies relied on inhibition of binding of an indicator peptide to MHC DR4 molecules by unlabeled competitor peptides, an assay commonly used to evaluate MHCII-peptide interaction [72]. Although inhibition assays can provide reliable rank measures of relative affinities, the IC(50) values are not necessarily linear with Kd values. Also, Kd values refer to reactions at equilibrium, but the MHCII-peptide interaction has several steps with very slow kinetics and equilibrium is difficult or impossible to achieve. These reasons led McConnell and colleagues [72,73] to propose that study of complex kinetic stability with labeled peptides may be advanta-
geous over IC(50) or Kd values. Moreover, abundant experimental evidence indicates that MHCII-peptide complex stability is highly influenced by HLA-DM molecules [25,74,75]. Thus we conducted experiments to assess the stability of DR4/T* complex and DR4/QNT-5 complexes in the presence and absence of HLA-DM. These experiments showed that while the apparent Kd values of the two peptide complexes were not remarkably affected by HLA-DM (Table 2), the half-lives were significantly lower than those formed by a control viral epitope (DR4/HA), and notably, that DR4/ QNT-5 complexes were highly unstable even in absence of HLA-

DM.

The issue of peptide editing by HLA-DM has stimulated considerable research in identifying characteristics of class II-peptide complex that can influence the complex susceptibility to HLA-DM. Structural features, including peptide length [76], destabilizing amino-acid residues [77,78], the rigidity of the P1 pocket of the class II molecules [79], and both anchor interactions and hydrogen bonding [77,80–82] all have been shown to influence class II-peptide complex susceptibility to HLA-DM. In contrast with the limited availability until recently of structural data on HLA-DM’s interaction with class II MHC proteins [83–85], functional experimental data pointing out the important role of anchor residues in conferring class II-peptide stability to HLA-DM have been published [86,87]. Lazarski et al. and others show that dissociation kinetics in live cells remarkably influence immunogenicity of peptide-MHC complex in vivo [22,24,25] and that replacing non-optimal residues at anchor positions is a suitable way to gain resistance to HLA-DM and increase immunogenicity in vivo. In their work, poorly immunogenic epitopes can be converted to highly immunogenic epitopes in vivo by optimizing peptide anchor residues such as P4 and P6 that foster class II-peptide kinetic stability [25]. Similarly, Rinderknecht et al., observed increased HLA-DM resistance after substitutions in the P4 and P6 pockets [88]. By optimizing the P1 anchor residue we were able to convert DR4/QNT-5 into a stable complex. This could be interpreted as the action of HLA-DM in QNT-5 editing being oriented toward the P1 pocket as proposed by others [77,82,85,89,90], but whether or not the
increased stability to HLA-DM of QNT-Y could be attributed to synergistic effect on QNT-Y of anchor residues beyond P1 such as P4, P6 and P7 as suggested by Lazarski et al [24,25] and Rinderknecht et al [88] is a possibility that deserve further investigation.

To assess the relative immunogenicity of the parent QNT-5 and P1-optimized QNT-Y epitopes, DR4 transgenic mice were immunized with linear peptides T1BT* or T1BT*-Y, and CD4 T cell IFN-γ responses and anti-CS antibody responses were studied. The T1BT* linear peptide was selected for these studies because (i) this subunit vaccine candidate can be produced as a synthetic linear peptide at low cost (ii) the T1BT* sequence has already been used in clinical trials and shown to induce relative high anti-sporozoite titers and T cell responses in individuals of multiple MHC haplotypes [36,38] and (iii) in a P. berghei transgenic model that expresses the P. falciparum CS T*-Y constructs have in their serum IgG responses to T*. From our findings it is clear that additional epitope engineering can transiently improve IFN-γ responses and high anti-(NANP)6 antibody titers, which were not substantially improved by increasing MHC-peptide stability. These results do not fit with the expected relationship between T cell immunogenicity and MHC-peptide stability and particularly resistance to DM-mediated editing.

Why QNT-5 is more effective than QNT-Y in inducing long-term T cell and antibody responses currently is not clear, but at least two possibilities can be envisioned; First, the EWS PCSVT C sequence in QNT-5 has a high degree of homology with thrombospondin type-1 repeats (TSR-1) present in at least 41 human proteins [92,93], including thrombospondin-1, properdin and F-spondin extracellular matrix proteins [94,95]. Alignment of predicted DR4-binding epitopes from these self-proteins reveals considerable similarity with QNT-5 and QNT-Y at MHC pocket position P4 and P6 and potential T cell contact residues in position 5 and positions 8 to 12 (Table 5). Thus, T cells that prefer the C-terminus region of T* might be modulated to avoid autoimmune response, for example by Treg-based mechanisms, with the improved stability of QNT-Y resulting in increased modulation. Second, we are using a transgenic mouse model in which antigenic peptides are presented by a hybrid mouse/DR4 molecule [96] that might not have an optimal interaction with mouse DM molecule.

Taken together, our results indicate that the highly conserved QNT-5 Th epitope of T* can be improved for interaction with MHC DRβ1*04:01 molecules and for resistance to HLA-DM editing by inclusion of an optimal P1 residue, and that such epitope engineering can transiently improve IFN-γ and B cell responses. However, the improvement in immunogenicity was short-lived, and long-term immune responses were attenuated by the modification. From our findings it is clear that additional research is needed to understand the factors that govern immune responses to T*.

### Supporting Information

**Figure S1** Direct peptide-binding assays and calculation of apparent binding affinity (Kd). (A) Amino-acid sequence

**Table 5.** Homology of the *P. falciparum* CS protein sequence in QNT-5 (strain NF54) and selected self-proteins.

| Protein                  | Sequence ID                     | Sequence |
|-------------------------|--------------------------------|----------|
| CS T*                   | spj|P195972|CSPLAFO | QNSLSTENSPCSVT C |
| CS T*-Y                 | gb|AAK34948.1|AF251058.1 | PKY-AQ-****-T-   |
| Thrombospondin human    | gb|AA863279.1 | RW-GST-****-G |
| Properdin               | dbj|BAB18461.1 | LL-PWS-****-D-|

1 Underlined are MHC anchor residues in P1, P4, and P6; dashes indicate identical residues.
and location of T*-1 and QNT-5 epitopes in T*. (B) Plots showing direct binding profile to DR4 of HA, T*, T*-1 and QNT-5-biotin labeled peptides upon binding reactions set up with or without 1 μM of HLA-DM (closed and open symbols respectively). The biotin labeled peptide/DR4 complexes carried out in duplicates was revealed using DR-ELISA; the values plotted as fraction bound are normalized to maximum binding achieved by 72 hours. The figure shows one representative experiment out of three performed. Range of K values found in reactions performed with and without HLA-DM are shown in table 2. (TIF)

Table S1 Relative IC50 values of Alamine substitution analogues and truncated versions of QNT-5.

(DOCX)

References

1. WHO (2011) WORLD HEALTH STATISTICS 2011. WHO Library Cataloguing-in-Publication Data.
2. Nussenzweig RS, Vanderberg J, Most H, Orton C (1967) Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216: 160–162.
3. Clyde DF (1975) Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. The American journal of tropical medicine and hygiene 24: 392–397.
4. Rieckmann KH (1990) Human immunization with attenuated sporozoites. Bulletin of the World Health Organization 68 Suppl: 13–16.
5. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, et al. (2002) Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. The Journal of infectious diseases 185: 1135–1146.
6. Edelman R, Hoffman SL, Davis JR, Beier M, Sztein MB, et al. (1993) Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. The Journal of infectious diseases 165: 966–970.
7. Seder RA, Chang LJ, Enama ME, Zephr KL, Sarvar UN, et al. (2013) Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341: 1359–1365.
8. Kumar KA, Sano G, Boscardin S, Nussenzweig RS, Nussenzweig MC, et al. (2006) The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444: 937–940.
9. Mootry VS, Balou WR (2009) Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malaria journal 8: 312.
10. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, et al. (2001) Protective efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. The Journal of infectious diseases 183: 640–647.
11. Rodrigues M, Nussenzweig RS, Zavala F (1993) The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria. Immunology 105: 1–5.
12. Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS (1979) Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bulletin of the World Health Organization 57 Suppl 1: 165–173.
13. Cochrane AH, Santoro F, Nussenzweig V, Gwadz RW, Nussenzweig RS (1982) Monoclonal antibodies identify the protective antigens of sporozoites of Plasmodium knowlesi. Proceedings of the National Academy of Sciences of the United States of America 79: 3651–3655.
14. Yoshida N, Nussenzweig RS, Potoczak P, Nussenzweig V, Akawo M (1988) Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207: 71–73.
15. Zavala F, Tam JP, Hollingsdale MR, Cochrane AH, Quakyi I, et al. (1985) Rational for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 225: 1436–1440.
16. Charoenwit Y, Melbou S, Cole C, Bechara R, Leef MF, et al. (1991) Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. Journal of immunology 146: 1020–1025.
17. Herrington DA, Clyde DF, Davis JR, Baqar S, Murphy JR, et al. (1990) Human studies with synthetic peptide sporozoite vaccine (NANP)3TT and immunization with irradiated sporozoites. Bulletin of the World Health Organization 68 Suppl: 33–37.
18. Good MF, Pombo D, Quakyi IA, Emily EM, Houghten RA, et al. (1988) Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci U S A 85: 1199–1203.
19. Nardin EH, Oliveira GA, Calvo-Calle JM, Castro ZR, Nussenzweig RS, et al. (2000) Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccines of defined HLA genotypes. J Infect Dis 182: 1406–1409.
20. Stem LJ, Brown JH, Jarrettzky TS, Gorga JC, Urban RG, et al. (1994) Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368: 215–221.
21. Sun Y, Calvo-Calle JM, Dominguez-Amoroso O, Stem LJ (2012) HLA-DM Constrains Epitope Selection in the Human CD4 T Cell Response to Vaccinia Virus by Favoring the Presentation of Peptides with Longer HLA-DM-Mediated Half-Lives. The Journal of Immunology 189: 3983–3994.
22. Sant AJ, Chaves FA, Jokal B, Meneses P, et al. (2003) The relationship between immunodominance, MD editing, and the kinetic stability of MHC class II peptide complexes. Immunol Rev 207: 261–278.
23. Hall FC, Rabiniwotz JD, Busch R, Visonti KC, Belmar R, et al. (2002) Relationship between kinetic stability and immunogenicity of HLA-DR4/peptide complexes. Eur J Immunol 32: 662–670.
24. Lazarsi CA, Chaves FA, Jenks SA, Wu S, Richards KA, et al. (2005) The Kinetic Stability of MHC Class II Peptide Complexes Is a Key Parameter that Dictates Immune Domination. Immunity 23: 29–40.
25. Lazarsi CA, Chaves FA, Sant AJ (2006) The impact of DM on MHC class II-restricted antigen presentation can be altered by manipulation of MHC-kinetic peptide kinetic stability. J Exp Med 203: 1319–1320.
26. Sun P, Schwenk R, White K, Stoute JA, Cohen J, et al. (2003) Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol 171: 6961–6967.
27. Reece WH, Pauler M, Godard PK, Milligan B, Bojang K, et al. (2004) A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 10: 496–500.
28. Sinagpura F, Guttinger M, Kalin J, Doran DM, Matile H, et al. (1988) A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 336: 778–780.
29. Doolan DL, Southwood S, Chensam R, Appella E, Gomez E, et al. (2000) HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol 165: 1123–1127.
30. Moreno A, Clavijo P, Edelman R, Davis J, Sztain M, et al. (1993) CD8+ T-cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J Immunol 151: 489–499.
31. Nardin EH, Herrington DA, Davis J, Levitt M, Stuber D, et al. (1989) Conserved repetitive epitope recognized by CD8+ clones from a malaria-immunized volunteer. Science 246: 1603–1606.
32. Moreno A, Clavijo P, Edelman R, Davis J, Sztain M, et al. (1993) Cytotoxic CD8+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. Int Immunol 5: 997–1003.
33. Guttinger M, Caspers P, Takas B, Tretiack A, Gillesden D, et al. (1988) Human T cells recognize polymorphic and non-polymorphic regions of the Plasmodium falciparum circumsporozoite antigen. The EMBO journal 7: 2555–2558.
34. Wang R, Epstein J, Charpentier Y, Baracat MR, Rahardjo N, et al. (2004) Induction in humans of CD4+ and CD8+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J Immunol 172: 5561–5569.
35. Schwenk R, Lumsden JM, Rein LE, Juompan L, Kester KE, et al. (2011) Immunization with the RTS,S/AS malaria vaccine induces IFN-gamma(+)CD4(+) T cells that recognize only discrete regions of the circumsporozoite protein and these specificities are maintained following booster immunizations and challenge. Vaccine 29: 8047–8054.
36. Calvo-Calle JM, Oliveira GA, Nardin EH (2005) Human CD4+ T cells induced by synthetic peptide malaria vaccine are comparable to cells elicited by attenuated Plasmodium falciparum sporozoite. J Immunol 175: 7355–7365.
37. Calvo-Calle JM, Hammer J, Sinagpura F, Clavijo P, Moya-Castro ZR, et al. (1997) Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell...
epitope in the Plasmodium falciparum circumsporozoite protein. J Immunol 159: 1362–1373.
38. Nardin EH, Calvo-Calle JM, Oliveira GA, Nussenzweig RS, Schreider M, et al. (2001) A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum RBS. A universal candidate vaccine that elicits immune responses in volunteers of diverse HLA types. J Immunol 166: 481–489.
39. Parra-Lopez C, Calvo-Calle JM, Cameron TO, Vargas LE, Salazar LM, et al. (2006) Major histocompatibility complex and T-cell interactions of a universal T-cell epitope from Plasmodium falciparum circumsporozoite protein. J Biol Chem 281: 14907–14917.
40. Houghten RA (1985) General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antibody-antigen interaction at the level of individual amino acids. Proc Natl Acad Sci U S A 82: 5133–5137.
41. Cameron TO, Norris DJ, Patel A, Moulder C, Rosenberg ES, et al. (2002) Labeling antigen-specific CD4+ T cells with class II MHC oligomers. J Immunol Methods 266: 51–69.
42. Frayser M, Sato AK, Xu L, Stern LJ (1999) Empty and peptide-loaded class II major histocompatibility complex proteins produced by expression in Escherichia coli and folding in vitro. Protein Expr Purif 15: 105–114.
43. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, et al. (1995) Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375: 802–806.
44. Henmecke J, Wiley DC (2002) Structure of a complex of the human alpha/beta T cell receptor (TCR) with HLA-A1, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DR4*0101 and DQB1*0401): insights into TCR cross-restriction and allodegeneracy. J Exp Med 195: 571–581.
45. Bolin DR, Swain AL, Sarabu R, Berdler SJ, Gillespie P, et al. (2000) Peptide and polypeptide mimics of antigen presentation by HLA class II molecules. Design, structure–activity relationships, and X-ray crystal structures. J Med Chem 43: 2133–2148.
46. Zavala F, Cochrane AH, Nardin EH, Nussenzweig RS, Nussenzweig V (1983) Circumsporozoite protein of malaria parasites contains a single immunodominant region with two or more identical epitopes. The Journal of experimental medicine 157: 1947–1957.
47. Moser JM, Sassano ER, Leistritz dH, Estrades JM, Phogat S, et al. (2010) Optimization of a dendritic cell-based assay for the in vitro priming of naive human CD4+ T cells. J Immunol Methods 355: 8–18.
48. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC (1997) X-ray crystal structure of HLA-DR1 (DRB1*0401 and DQA1*0101, DRB1*0401): insight into TCR cross-restriction and allodegeneracy. J Exp Med 195: 571–581.
49. Brown DR, Fastenau PS, Schild D, Bibler DR, Lohmann JA, et al. (2008) Structural analysis of HLA-DM and HLA-DS induced conformational changes in a binary complex. J Immunol 180: 2555–2565.
50. Rosloniec EF, Whittington KB, Zaller DM, Elyaj, et al. (2002) Enhanced antigen-specific T-cell responses with a peptide blocker. Cell 99: 167–176.
51. de la Cruz VF, Lal AA, McCutchan TF (1987) Sequence variation in putative functional domains of the circumsporozoite protein of Plasmodium falciparum. Implications for vaccine development. J Biol Chem 262: 11933–11939.
52. Yosiada N, Di Santi SM, Dutra AP, Nussenzweig RS, Nussenzweig V, et al. (1997) Plasmodium falciparum: restricted polymorphism of T-cell epitopes of the circumsporozoite protein in Brazil. Exp Parasitol 86: 775–781.
53. Esclante AA, Cornejo OE, Rojas A, Udhayakumar V, Lal AA (2004) Assessing the effect of natural selection in malaria parasites. Trends Parasitol 20: 388–395.
54. Chou CL, Sadegh-Nasseri S (2000) HLA-DM recognizes the flexible terminal region and the MHC class II alpha-chain. J Immunol 172: 1109–1117.
55. Belmares MP, Busch H, Wucherpenng KW, McConnell HM, Mullin ED (2002) Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 194: 833–846.
56. Zirkle KM, Zahnd C, Neuberg D, Gribben JG (2006) Cytotoxic T cells generated against heterologous peptides kill primary tumor cells independently of the binding affinity of the native tumor antigen peptide. Blood 108: 3865–3870.
57. McFarland BJ, Besser C (2002) Binding interactions between peptides and proteins of the class II major histocompatibility complex. Med Res Rev 22: 168–188.
58. Kasson PM, Rabinowitz JD, Schmitt L, Davis MM, McConnell HM (2000) Kinetics of peptide binding to the class II MHC protein I-Ek. Biochemistry 39: 1048–1058.
59. Amiria S, Hajarizadehnoori LM, Harboes C, Zhao D, Goldstein O, et al. (2006) HLA-DM negatively regulates HLA-DR-restricted classical pathogenic peptide presentation and T cell recognition. J Immunol 178: 1961–1970.
60. Behmades MP, Busch R, Wucherpenng KW, McConnell HM, Mullin ED (2002) Structural factors contributing to DM susceptibility of MHC class II/ peptide complexes. J Immunol 168: 473–481.
61. Sridhar V, Vogt AB, Kropshover H, Falconi F, Molina M, et al. (1998) Binding affinity independent contribution of peptide length to the stability of peptide–HLA-DR complexes in live antigen presenting cells. Hum Immunol 59: 463–474.
62. Narayan K, Chow CL, Kim A, Hartman IL, Dalai S, et al. (2007) HLA-DM targets the hydrogen bond between the histidine at position beta1 and peptide to dissociate HLA-DR-peptide complexes. Nat Immunol 8: 92–100.
63. Bhatia K, Besser C, Kropshover H, Galliani F, et al. (1999) Identification of destabilizing residues in HLA class II-selected bacteriophage display libraries edited by HLA-DM. Eur J Immunol 29: 660–668.
64. Cho CL, Saifeh-Ganasser S (2000) HLA-DM recognizes the flexible conformation of major histocompatibility complex class II. J Exp Med 192: 1697–1706.
65. McFarland BJ, Besser C, Sant AJ (1999) Cutting edge: a single, essential hydrogen bond controls the stability of peptide–MHC class II complexes. J Immunol 163: 3567–3571.
66. McFarland BJ, Katz JF, Sant AJ, Besser C (2005) Energetics and cooperativity of the hydrogen bonding and anchor interactions that bind peptides to MHC class II protein. J Mol Biol 350: 170–183.
67. Strankos E, Wiley DC, Stern LJ (2008) Enhanced catalytic action of HLA-DM on the exchange of peptides lacking backbone hydrogen bonds between their N-terminal region and the MHC class II alpha-chain. J Immunol 172: 1109–1117.
68. Guay AC, Mortimer SE, Yoon T, Painter CA, Jiang W, et al. (2013) HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. Nat Struct Mol Biol 20: 90–98.
69. Jensen PE (1998) Antigen processing. HLA-DO—a hitchhiking inhibitor of HLA-DM. Curr Biol 8: R126–131.
70. Gros OR, Guay AC, Mortimer SE, Yoon T, Painter CA, Jiang W, et al. (2013) HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. Nat Struct Mol Biol 20: 90–98.
71. Jeunes PE (1998) Antigen processing. HLA-DO—a hichhiking inhibitor of HLA-DM. Curr Biol 8: R126–131.
72. Pos W, Sethi DK, Call MJ, Schulze MS, Anders AK, et al. (2012) Crystal structure of the HLA-DM–DR1 complex defines mechanisms for rapid peptide selection. Cell 151: 1557–1568.
73. Chaves FA, Richards KA, Torelli A, Wedekind J, Sant AJ (2006) Peptide-binding motifs for the I-Ad MHC class II molecule: alternate pH-dependent binding conformations. Biochemistry 45: 6426–6433.
74. Ferrante A, Gorski J (2007) Cooperativity of hydrophobic anchor interactions: evidence for epitope selection by MHC class II as a folding process. J Immunol 179: 7181–7189.
88. Rinderknecht CH, Roh S, Pashine A, Belmares MP, Patil NS, et al. (2010) DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms. Immunology 131: 18–32.

89. Pashine A, Bosch R, Belmares MP, Munning JN, Doebel R, et al. (2003) Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity 19: 183–192.

90. Anders AK, Call MJ, Schulze MS, Fowler KD, Schubert DA, et al. (2011) HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptide. Nat Immunol 12: 54–61.

91. Carapau D, Mitchell R, Nacer A, Shaw A, Othoro C, et al. (2013) Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin. Infection and Immunity 81: 4350–4362.

92. Tan K, Duquette M, Liu JH, Dong Y, Zhang R, et al. (2002) Crystal structure of the TSP-1 type 1 repeat: a novel layered fold and its biological implication. J Cell Biol 159: 373–382.

93. Tucker RF (2004) The thrombospondin type 1 repeat superfamily. Int J Biochem Cell Biol 36: 969–974.

94. Adams JC (2001) Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol 17: 25–51.

95. Klar A, Baldassare M, Jessell TM (1992) F-spondin: a gene expressed at high levels in the floor plate encodes a secreted protein that promotes neural cell adhesion and neurite extension. Cell 69: 95–110.

96. Woods A, Chen HY, Trumbauer ME, Sirotina A, Cummings R, et al. (1994) Human major histocompatibility complex class II-restricted T cell responses in transgenic mice. J Exp Med 180: 173–181.

97. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, et al. (1987) Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 320: 257–259.